These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20425376)

  • 1. Management of advanced-stage peripheral T-cell lymphomas.
    Kimby E
    Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
    Gallamini A; Zaja F; Patti C; Billio A; Specchia MR; Tucci A; Levis A; Manna A; Secondo V; Rigacci L; Pinto A; Iannitto E; Zoli V; Torchio P; Pileri S; Tarella C
    Blood; 2007 Oct; 110(7):2316-23. PubMed ID: 17581918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
    Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
    Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.
    Buckstein R; Fraser G; Cheung M; Kukreti V; Kuruvilla J; Imrie K; Piliotis E; Pond G; Windsor J; Ghorab Z; Shuoprasad K; Turner R; Meyer RM; Pritchard K; Walker S; Levine M; Crump M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):18-28.e4. PubMed ID: 26711181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
    Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
    Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral T-cell lymphoma--not otherwise specified.
    Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
    Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
    Kluin-Nelemans HC; van Marwijk Kooy M; Lugtenburg PJ; van Putten WLJ; Luten M; Oudejans J; van Imhoff GW
    Ann Oncol; 2011 Jul; 22(7):1595-1600. PubMed ID: 21212158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
    Chen AI; Advani RH
    J Natl Compr Canc Netw; 2008 Apr; 6(4):428-35. PubMed ID: 18433608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
    Franco CM; Popplewell LL; Horwitz SM
    Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.